Leo Pharma and Astrazeneca keep future plans tight for tralokinumab
Neither Leo Pharma nor Astrazeneca wants to reveal the future plans for tralokinumab, which has just been approved as an atopic eczema treatment in the US. The drug has blockbuster potential in the approved indication, and while other indications might be considered, Astrazeneca retains the rights for several lucrative indications.
by ULRICH QUISTGAARD, translated by daniel pedersen
The US approval of Leo Pharma's eczema drug, tralokinumab, has been a popular topic at the Danish dermatology firm, which has clear blockbuster expectations for the treatment.